[HTML][HTML] Diabetic neuropathy: what does the future hold?

BC Callaghan, G Gallagher, V Fridman, EL Feldman - Diabetologia, 2020 - Springer
Frustratingly, disease-modifying treatments for diabetic neuropathy remain elusive.
Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but …

[HTML][HTML] Diabetic neuropathy: what does the future hold?

BC Callaghan, G Gallagher, EL Vera Fridman - Diabetologia, 2020 - Springer
New treatments for diabetic neuropathy are needed since glycaemic control is not the
complete answer. In this issue, Callaghan et al (https://doi. org/10.1007/s00125-020-05085 …

Diabetic neuropathy: what does the future hold?

BC Callaghan, G Gallagher, V Fridman… - …, 2020 - search.proquest.com
Frustratingly, disease-modifying treatments for diabetic neuropathy remain elusive.
Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but …

[HTML][HTML] Diabetic neuropathy: what does the future hold?

BC Callaghan, G Gallagher, V Fridman… - Diabetologia, 2020 - ncbi.nlm.nih.gov
Frustratingly, disease-modifying treatments for diabetic neuropathy remain elusive.
Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but …

Diabetic neuropathy: what does the future hold?

BC Callaghan, G Gallagher, V Fridman… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Frustratingly, disease-modifying treatments for diabetic neuropathy remain elusive.
Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but …

Diabetic neuropathy: what does the future hold?

BC Callaghan, G Gallagher, V Fridman, EL Feldman - Diabetologia, 2020 - europepmc.org
Frustratingly, disease-modifying treatments for diabetic neuropathy remain elusive.
Glycaemic control has a robust effect on preventing neuropathy in individuals with type 1 but …

Diabetic neuropathy: what does the future hold?

BC Callaghan, G Gallagher, EL Vera Fridman - Diabetologia, 2020 - search.proquest.com
New treatments for diabetic neuropathy are needed since glycaemic control is not the
complete answer. In this issue, Callaghan et al (https://doi. org/10.1007/s00125-020-05085 …